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Abstract
Background: Bitter gourd (Momordica charantia L.) is a common tropical vegetable that has been used in traditional
or folk medicine to treat diabetes. Wild bitter gourd (WBG) ameliorated metabolic syndrome (MetS) in animal models.
We aimed to preliminarily evaluate the effect of WBG supplementation on MetS in Taiwanese adults.
Methods: A preliminary open-label uncontrolled supplementation trial was conducted in eligible fulfilled the
diagnosis of MetS from May 2008 to April 2009. A total of 42 eligible (21 men and 21 women) with a mean age of
45.7 ± 11.4 years (23 to 63 years) were supplemented with 4.8 gram lyophilized WBG powder in capsules daily for
three months and were checked for MetS at enrollment and follow-up monthly. After supplementation was
ceased, the participants were continually checked for MetS monthly over an additional three-month period. MetS
incidence rate were analyzed using repeated-measures generalized linear mixed models according to the
intention-to-treat principle.
Results: After adjusting for sex and age, the MetS incidence rate (standard error, p value) decreased by 7.1% (3.7%,
0.920), 9.5% (4.3%, 0.451), 19.0% (5.7%, 0.021), 16.7% (5.4%, 0.047), 11.9% (4.7%, 0.229) and 11.9% (4.7%, 0.229) at visit
2, 3, 4, 5, 6, and 7 compared to that at baseline (visit 1), respectively. The decrease in incidence rate was highest at
the end of the three-month supplementation period and it was significantly different from that at baseline (p =
0.021). The difference remained significant at end of the 4th month (one month after the cessation of
supplementation) (p = 0.047) but the effect diminished at the 5th and 6th months after baseline. The waist
circumference also significantly decreased after the supplementation (p < 0.05). The WBG supplementation was
generally well-tolerated.
Conclusion: This is the first report to show that WBG improved MetS in human which provides a firm base for
further randomized controlled trials to evaluate the efficacy of WBG supplementation.
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Introduction
Bitter gourd (Momordica charantia L.; BG) is a com-
mon tropical vegetable that has also been used in the
traditional medicine. BG’s anti-diabetic, anti-bacterial,
antiviral and anticancer activities have been scientifically
demonstrated in past decades [1,2]. Among these, the
anti-diabetic activity and possible mechanisms of BG
have been demonstrated in molecular, cellular and ani-
mal models as well as in human studies and extensively
reviewed [3-5]. In addition, BG has been shown to ame-
liorate metabolic syndrome (MetS) in animal studies
[6-8]. Nevertheless, it remains unclear if BG has benefi-
cial effects on MetS in human.
MetS is a metabolic disorder characterized by the
clustering of risk factors including: abdominal obesity,
dyslipidemia, hypertension and insulin resistance, and is
well-established for predicting high risks of type 2 dia-
betes mellitus (DM), cardiovascular diseases [9] and all
causes mortality [10]. Due to rapid transitions toward
excessive energy intake and sedentary lifestyle, MetS has
become a major health problem worldwide affecting
about 34% of US [11] and 23.1% of Taiwan populations
[12].
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bohydrates and lipid metabolism, is considered to play a
central role in MetS. Peroxisome proliferator-activated
receptors (PPARs) are nuclear receptors that control lipid
and carbohydrate metabolism. These receptors are
regarded as important targets for treating MetS [13]. BG
extract activated PPARa [14] and PPARg [15,16], and thus
were recognized as a PPARa/g dual agonist [17]. In animal
models, BG up-regulated PPARg and PPARa-mediated
pathways which is associated with improved MetS [6,18].
Together with other evidences that BG improved insulin
signaling [8], BG is considered a potential “traditional Chi-
nese medicines” in treating MetS [19].
To date, most published human clinical trials on BG
were focused on the blood glucose control [20], very
few were on the MetS. This study aimed at preliminarily
exploring the potential effects of WBG on MetS. It is
anticipated to learn from this preliminary study the
safety, feasibility and validity of experimental design,
including subject inclusion and exclusion criteria,
dosage, period of supplementation, length of washout
period, endpoint for examination, etc., to support double




Fresh Hualien No. 4 wild bitter gourds (Momordica
charantia L.; WBG) were developed, cultivated and pro-
vided by Hualien District Agricultural Research and
Extension Station, Council of Agricultural, Executive
Yuan, Taiwan. This specific hybrid strain was selected
based on its high activity in the PPAR transactivation
assay. A total of 502.8 kg fresh WBG (whole fruit
including seeds) was lyophilized and pulverized. The
dried WBG powder (27.4 kg) was filled into capsules
(480 mg in each). The preparation of WBG capsules
from fresh WBG was conducted by a GMP factory
(Family Satisfied BIO-CHEM Co., Changhua, Taiwan)
under our instruction and supervision.
Subjects and Design
Study subjects
The study was approved by the Institutional Review
Board (IRB) of Cheng Ching Hospital (Taichung, Tai-
wan). Candidates (≥20 years) were recruited at this hos-
pital and screened. Eligible subjects were invited and
informed of the purpose and risks of the study and their
written informed consents were obtained.
Definition of MetS and Exclusion criteria
Candidates having three or more of the following five
features met the diagnostic criteria for MetS: (1) waist
circumference ≥90 cm in men and ≥80 cm in women,
(2) serum triglyceride ≥150 mg/dL, (3) high density
lipoprotein cholesterol (HDL-c) < 40 mg/dL in men and
< 50 mg/dL in women, (4) blood pressure ≥130/85 mm
Hg, and (5) serum glucose ≥100 mg/dL [9,21]. Major
exclusion criteria included: serum alanine aminotrans-
ferase ≥100 IU/L (3 times the upper limit of normal
value), total bilirubin ≥2.0 mg/dL, creatinine ≥2.0 mg/
dL, glycosylated hemoglobin (HbA1c) levels ≥9.0%,
women of childbearing potential not using adequate
contraception [2], diagnosed myocardial infarction,
unstable angina or cerebral vascular attack in the pre-
vious six months, receiving vigorous exercise training,
weight control with diet or drug, presence of conditions
affecting compliance (i.e., drug, alcohol abuse or psy-
chiatric problems), and unwillingness to consent. Those
with allergies to foods of the melon family and with
known G6PDH deficiency [2] were also excluded.
Sample size estimation
The estimation of the sample size was based on a 15%
decrease in the incidence rate of MetS. As such, the
investigation had more than 80% power to detect any
15% decrease in the incidence rate of MetS status at a
significance level of 0.05. The expected dropout rate was
5%. More than 45 eligible patients were targeted for
recruitment.
Study Design
This preliminary trial was regarded as a phase II
(exploratory efficacy)-like study using an open-label sin-
gle-arm design to generate hypothesis, to determine the
safety (adverse effect) and to provide justification for a
large-scale multicenter clinical trial in the future. Based
on our previous animal study and the study reported by
Jayasooriya et al [22], 1% (w/w) WBG in the diet signifi-
cantly improved hyperglycemia and lipid metabolism.
The dose of supplementation in this study was set at
4.5-5.0 g WBG/day as Taiwanese 24-hour diets were
estimated to weigh 450-500 g on a dry basis [23]. Stu-
died subjects were instructed to take three, three and
four capsules with their three daily meals without alter-
ing their usual dietary and exercise habit. The MetS risk
factors were monitored monthly throughout the three
successive months of supplementation. After the cessa-
tion of supplementation, MetS risk factors were conti-
nually followed up over an additional three-month
period. Thus, a total of seven visits was needed to com-
p l e t et h es t u d y( v i s i t1w a st h eb a s e l i n eb e f o r et h es u p -
plementation started). At each visit, subjects were
interviewed regarding compliance and adverse events.




The primary efficacy endpoint (outcome measurement)
was a decline in the % MetS incidence after the
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were the 5 diagnostic criteria for MetS and the insulin
resistance indicators including homeostasis model
assessment (HOMA), logHOMA, quantitative insulin
sensitivity check index (Quicki) and McAuley index.
These indicators were calculated as the followings:
HOMA = insulin (μU/mL) × 0.8 glucose (mg/dL);
QUICKI = 1/[log insulin (μU/mL) + log glucose (mg/
dL)]; McAuley Index = exp [2.63-0.28 ln insulin (μU/
mL) -28.35 ln triglycerides (mg/dL)]. Decreases of Homa
& log Homa as well as increases of QUICKI and McAu-
ley index values indicate the amelioration of insulin
resistance.
Safety
In human trials of BG, the most commonly reported
side effects are abdominal pain and diarrhea [24]. Aside
from adverse events, other surrogate laboratory safety
endpoints monitored were serum creatinine, hepatic
transaminases (alanine aminotransferase and aspartate
aminotransferase), g-glutamyl transferase, alkaline phos-
phatase, total bilirubin, sodium and potassium.
Physical examination
Weight, height, waist circumference, and blood pressure
were measured by trained nurses, who also took blood
samples. Weight and height were measured to the near-
est 0.1 kg and 0.1 cm, respectively. Body mass index
(BMI) was calculated as body weight in kilograms
divided by the square of height in meters. Waist circum-
ference was measured midway between the costal mar-
gin and iliac crest to the nearest 0.1 cm. At each visit,
the blood pressure was measured 3 times with manual
mercury sphygmomanometer and the mean value was
recorded.
Blood specimen collection and analysis
Fasting blood specimens were collected after an eight-
hour overnight fast. The blood samples were sent to the
clinical laboratory of Cheng Ching Hospital for analysis
within one hour. Anti-coagulated whole blood was used
to determine erythrocyte count, leukocyte count, hemo-
globin, and platelet count using a Cell Dyn
® 3500 hema-
tology AutoAnalyzer (Abbott Laboratories, Dallas, TX,
US). Biochemical tests were performed using a Hitachi
®
747 analyzer (Roche Diagnostics, Mannheim, Germany).
Data Analysis
Significance of the change in the MetS incidence rate
was analyzed by the repeated-measures generalized lin-
ear mixed model (GLMM). Those of the secondary effi-
cacy endpoints which were continuous variables were
analyzed by the linear mixed model (LMM). Irrespective
of whether the study subject has completed the whole
study or not, data of the 42 study subjects were all
included in the statistical analyses based on the “inten-
tion-to-treat” principle to avoid bias. The p values set
the significance level at 0.05 were one-sided. The IBM
SPSS




Among 58 participants assessed for eligibility, 42 (72.4%)
met the inclusion criteria of MetS and 16 (27.6%) were
excluded including 10 not meeting inclusion criteria and
6 refusing to participate in this trial. Among the 42 eli-
gible enrolled, 38 completed the trial. The reasons of
withdrawals were: two went abroad and two discontin-
ued because of dizziness and headache.
Of the 42 study subjects, 21 (50%) were men and 21
(50%) were women. The study subjects had a median
age (inter-quartile range; IQR) and mean age (range) of
49 years (35-54), 45.7 ± 11.4 years (23-63) respectively.
Test of normality of age with Shapiro-Wilk test showed
that p-value is 0.096, indicating that these data are from
a normally distributed population. Eighteen (42.9%), 18
( 4 2 . 9 % )a n d6( 1 4 . 3 % )w i t h3 ,4a n d5c r i t e r i ao fM e t S
respectively were noted. Among the 42 subjects, 40
(95.2%) had abdominal obesity (based on waist circum-
ference), 14 (33.3%) were overweight (24 < BMI < 27
kg/m
2) and 26 (61.9%) were obese (BMI≥27 kg/m
2). The
numbers of subjects with other MetS risk factors were
26 (61.9%) with serum glucose ≥100 mg/dL, 34 (81.0%)
with serum triglyceride ≥1 5 0m g / d L ,2 5( 5 9 . 5 % )w i t h
low HDL-c and 36 (85.7%) with SBP ≥130 or DBP≥ 85
mmHg. Additional characteristics of the study subjects
included: tobacco use 7 (16.7%), alcohol consumption 2
(4.8%), betel nut chewing 1 (2.4%) and exercise 14
(33.3%).
The baseline characteristics of the 42 subjects, strati-
fied by gender, are presented in Table 1. The following
characteristics were significantly different between gen-
ders: body height, HDL-c, alanine aminotransferase,
aspartate aminotransferase, g-glutamyl transferase, total
bilirubin, creatinine, uric acid, homocysteine, testoster-
one, C-reactive protein, red blood cell, hemoglobin, pla-
telet, HOMA and McAuley index. No significant
differences were noted between the two groups in terms
of age, body weight, body mass index, waist circumfer-
ence, blood pressure, heart rate, fasting glucose, glycosy-
lated hemoglobin A1c, triglyceride, low density
lipoprotein cholesterol (LDL-c), cholesterol, alkaline
phosphatase, insulin, fibrinogen, white blood cell,
logHOMA and Quicki.
Effects of WBG on MetS
Changes in the incidence rate of MetS throughout the
study are shown in Figure 1. The GLMM analyses were
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adjusting for sex and age, the decreases in the incidence
rate (standard error, p v a l u e )o fM e t Sa tv i s i t2 ,3 ,4 ,5 ,
6a n d7f r o mt h eb a s e l i n ev a l u e( v i s i t1 )w e r e :7 . 1 %
(3.7%, 0.920), 9.5% (4.3%, 0.451), 19.0% (5.7%, 0.021),
16.7% (5.4%, 0.047), 11.9% (4.7%, 0.229) and 11.9%
(4.7%, 0.229) respectively. The incidence rate was lowest
at the end of the three-month supplementation period
(visit 4) and was significantly lower than that at the
baseline which is 100% (p = 0.021). It still remained sig-
nificant at visit 5 (one month after the cessation of sup-
plementation) (p = 0.047) but this effect diminished at
visit 6 & 7 (two & three months after stopping
supplementation) (p > 0.05). The decreases were not sig-
nificant when the two genders were analyzed separately.
Except for waist circumference, the remaining four
risk factors of MetS did not show significant decreases
after WBG supplementation. In contrast, significant
decreases in the waist circumference were observed after
the intervention (Table 2). Compared to the value at the
baseline (visit 1), there were significant decreases in the
waist circumference at visit 3 (p < 0.0001), visit 4 (p =
0.002) and visit 5 (p = 0.042).
When women and men were separately analyzed after
adjusting for age, the decreases of the waist circumference
were still significant (Table 2). Compared to the baseline,
Table 1 Baseline characteristics and differences between genders (n = 42)
Variables Men mean SEM
a Women mean SEM
a p value
b
Age (year) 46.9 2.7 44.4 2.3 0.487
Body height (cm) 170.1 1.6 160.0 1.2 0.000
Body weight (kg) 82.4 3.1 77.1 3.4 0.258
Body mass index (kg/m
2) 28.4 0.7 30.0 1.1 0.225
Waist circumference (cm) 98.4 1.8 94.4 2.3 0.181
Systolic blood pressure (mm Hg) 140.0 3.3 137.7 3.7 0.631
Diastolic blood pressure (mm Hg) 93.5 3.2 88.2 2.3 0.187
Heart rate (beat/min) 75.1 2.5 77.7 2.2 0.448
Fasting sugar (mg/dL) 112.8 5.8 105.4 5.0 0.339
Hemoglobin A1c
c (%) 6.4 0.3 6.3 0.2 0.684
Triglyceride (mg/dL) 234.0 23.8 188.4 14.7 0.112
HDL-c
c (mg/dL) 41.5 1.7 49.3 2.1 0.006
LDL-c
c (mg/dL) 125.5 7.1 134.9 6.1 0.314
Total cholesterol (mg/dL) 195.2 7.7 204.9 6.2 0.333
Alanine aminotransferase (IU/L) 42.0 4.1 23.2 2.4 0.000
Aspartate aminotransferase (IU/L) 30.1 3.1 20.5 1.6 0.008
g-Glutamyl transferase (IU/L) 54.4 8.5 29.8 3.1 0.012
Alkaline phosphatase (IU/L) 161.3 7.8 142.2 9.8 0.135
Total bilirubin (mg/dL) 0.7 0.05 0.6 0.06 0.019
Creatinine (μm/L) 1.1 0.03 0.8 0.02 0.000
Uric acid (mg/dL) 7.8 0.29 6.1 0.27 0.000
Insulin (μIU/mL) 19.4 4.7 16.5 2.0 0.566
Homocysteine (μmol/L) 13.6 0.7 11.5 0.6 0.025
Testosterone (ng/dL) 337.2 25.0 31.6 3.7 0.000
Fibrinogen (mg/dL) 434.5 20.7 469.8 27.0 0.308
C-reactive protein (mg/dL) 0.28 0.06 0.51 0.12 0.001
White blood cell (k/μL) 7.3 0.4 7.2 0.5 0.792
Red blood cell (m/μL) 5.2 0.12 4.7 0.07 0.002
Hemoglobin (g/dL) 15.3 0.2 13.7 0.2 0.000
Platelet (k/μL) 259.1 11.0 312.4 11.9 0.002
HOMA
c 4.8 1.1 3.7 0.5 0.012
LogHOMA 0.56 0.07 0.51 0.05 0.096
Quicki
c 0.32 0.01 0.32 0.01 0.176
McAuley index 0.55 0.03 0.59 0.03 0.043
aSEM indicates standard error of mean.
bAnalyzed by t-test.
cHemoglobin A1c indicates glycosylated hemoglobin A1c. HDL-c indicates high density lipoprotein
cholesterol. LDL-c indicates low density lipoprotein cholesterol. HOMA indicates homeostasis model assessment. Quicki indicates quantitative insulin sensitivity
check index.
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for women at visit 3 and visit 4, but not at visit 6 and visit
7. In men, there were significant decreases at visit 2, 3, 5, 6
and 7. Interestingly, there were no significant decreases in
BMI after WBG supplementation.
Changes of the three insulin resistance indicators,
logHOMA, Quicki, and McAuley values, throughout the
study period are shown in Figure 2. The changes of
insulin resistance indicators logHOMA, McAuley, and
Quicki implied an ameliorative trend during the supple-
mentation period. Decreased logHOMA and increased
Quicki values showed improvement of insulin resistance
at visit 2 and returned to nearly baseline level after the
cessation of supplementation, but the differences did
not reach significant levels (p > 0.05). The increasing
trend of the McAuley values also suggested the
improvement which could be maintained throughout
the six month of the study period. The McAuley values
were highest at visit 6 (two months after the cessation
of supplementation) which was significantly different
from that of visit 1. Result of LMM analyses, after
adjusting for sex and age, showed the changes of the
HOMA values at visit 2, 3, 4, 5, 6, and 7 from the base-
line visit 1 were not significant (data not shown).
Side effect
There were few adverse events during the study and
these were generally mild. Throughout the three-month
supplementation period only one subject reported
abdominal pain and two claimed bloat. Neither upper
respiratory tract infections, rapid weight gain, edema,
nor other serious adverse events have been noted during
the three-month follow-up period. Two patients
dropped out due to persistent dizziness and headache
which already disturbed them on and off before entering
this study. There were no significant changes in the
alkaline phosphatase, g-glutamyl transferase, AST, ALT,
total bilirubin, creatinine, sodium and potassium levels
at visit 4 compared to those at the baseline (visit 1).
Discussion
Results of this preliminary study demonstrate, for the
first time, the beneficial effects of WBG in Taiwanese
adult subjects with MetS. A daily dose of 4.8 grams
Figure 1 Changes in the incidence rate of metabolic syndrome (MetS) throughout the study period.4 2s u b j e c t sw e r es u p p l e m e n t e d
with 4.8 g/d wild bitter gourd for three month. Metabolic syndrome was monitored monthly during the three-month supplementation (visit 1-
4) and another three months (visit 5-7) after the supplementation ended. *p < 0.05 denotes significantly different from the baseline value (visit 1)
analyzed by generalized linear mixed models after adjusting for sex and age.






b Mean (cm) SEM
a p value




c 0.13 0.88 0.878 -2.08 0.95 0.031 -0.99 0.66 0.138
Visit 3-Visit 1 -2.97 0.88 0.001 -2.04 0.95 0.034 -2.52 0.66 0.000
Visit 4-Visit 1 -2.50 0.86 0.004 -1.64 0.95 0.087 -2.09 0.66 0.002
Visit 5-Visit 1 -0.72 0.88 0.411 -1.96 0.95 0.042 -1.36 0.66 0.042
Visit 6-Visit 1 0.20 0.88 0.817 -2.69 0.95 0.006 -1.26 0.66 0.059
Visit 7-Visit 1 -0.08 0.89 0.925 -2.55 0.97 0.010 -1.32 0.67 0.051
aSEM indicates standard error of means.
bAnalyzed by linear mixed models.
cVisit 1 is the baseline.
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decreased the incidence of MetS after three months of
supplementation and the improved status remained after
stopping the supplementation for one month, but not
for two and three months. This indicates that the wash-
o u tp e r i o ds h o u l db ea tl e a s to n em o n t hi fac r o s s o v e r
s t u d yi st ob ec o n d u c t e d .O u rr e s u l t ss h o wt h a ti ti s
worth to conduct further randomized-placebo controlled
trials to confirm the benefits of WBG on metabolic
disorders.
MetS is a spectrum of metabolic disorders that project
to high risk of type 2 DM and cardiovascular diseases.
MetS subjects defined by at least three out of the five
risk factors are thus a heterogeneous population. The
most common characteristic of our study subjects is
abdominal obesity, based on the large waist circumfer-
ence (40 out of the 42 subjects). In this regard, we did
observe a significant decrease in waist circumference
after the supplementation of WBG. On the other hand,
the number of subjects with high serum glucose(≥100
mg/dL) and triglyceride(≥150 mg/dL), low HDL-c and
high blood pressure (SBP ≥130 or DBP≥ 85 mmHg)
were 26 (61.9%), 34 (81.0%), 25 (59.5%) and 36 (85.7%),
respectively. The relatively s m a l ls a m p l es i z et o g e t h e r
with the heterogeneity might have limited our power to
detect differences in these metabolic endpoints.
Insulin resistance is regarded to play a central role in
MetS and abdominal obesity has been associated with
insulin resistance. Despite that the insulin resistance
indicators logHOMA, McAuley, and Quicki showed
ameliorated trends after one to three months of WBG
supplementation, there were no statistical significance
due to the small sample size and heterogeneous charac-
teristics of our study subjects. Indeed, our original goal
was to recruit 45 MetS subjects based on the sample
size estimation with a 15% decrease in the MetS inci-
dence rate after WBG supplementation and 5% dropout
rate. Fortunately, a 19% decrease in the MetS incidence
rate was observed despite that only 42 subjects were
recruited and 4 (9.5%) of them have dropped out.
In addition to the individual differences in MetS risk
factors, the heterogeneity of our study subjects also
arisen from the great range of their ages (23-63 years)
and BMI (22.3-45.2). Moreover, both men and women
(irrespective of whether they are post- or pre- meno-
pause) were included. Besides, subjects previously diag-
nosed with type 2 DM, hyperlipidemia or hypertension
were not excluded and were all advised to maintain
their prescribed medication. These further increased the
heterogeneity of our study subjects. All these heteroge-
neities should be avoided if a randomized controlled
trial is to be carried out in the future.
Figure 2 Changes of logHOMA, Quicki and McAuley index, the insulin resistance indicators throughout the study period. 42 subjects
were supplemented with 4.8 g/d wild bitter gourd for three month. Insulin resistance index was monitored monthly during the three-month
supplementation (visit 1-4) and another three months (visit 5-7) after the supplementation ceased. Values are means and error bars are 1/2 SEM.
*p = 0.043 and ***p = 0.001 denote significantly different from the baseline value (visit 1) analyzed by linear mixed models after adjusting for
age and sex.
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extracts/components has been extensively reviewed and
various active compounds and action mechanisms have
been proposed [3-5]. Early study isolated a Polypeptide-
P, the so-called “plant insulin” from BG and demon-
strated its insulin-like activity [25]. D-(+)-trehalose iso-
lated from BG was shown to inhibit a-glucosidase [26]
and delayed the digestion and absorption of dietary car-
bohydrates. Recently, cucurbitane-type triterpenoids iso-
lated from BG were shown to increase glucose
transporter 4 translocation through activation of AMPK
[27], inhibit a-glucosidase [28], and modulate insulin
secretion activity [29]. 9c,11t,13t-conjugated linolenic
acid [30] and momordin [31] from BG were noted to
activate PPAR a, g and PPAR b/δ respectively. It has
been shown that PPARg agonist induced uncoupling
protein-1 expression and increased oxygen consumption
in the white adipose tissue cells [32]. In addition,
PPARb/δ has been shown to play a critical role in the
body fat reduction in an animal model [33].
In vivo studies using animal models also provided evi-
dences that BG ameliorated metabolic disorders through
the regulations of PPARs as one of the mechanism
[18,34]. The Hualien No.4 WBG used in this study is a
hybrid variety of WBG being selected for its high PPAR
activating activity. Other proposed mechanisms for
actions of BG include stimulation of pancreatic insulin
secretion [35], decreased hepatic gluconeogenesis,
increased hepatic glycogen synthesis, metformin- and
sulfonylurea-like glycemic control activities [5,36].
Almost all the human studies associated with meta-
bolic disorder using bitter gourd were focused on con-
trolling type 2 DM [3]. The beneficial effects of BG on
type 2 DM have not been firmly established. Most non-
controlled, and 2 randomized controlled trials [20,37]
showed statistically significant reduction of fasting blood
glucose, but other controlled trials showed no significant
effect [20].
Among the five criteria of MetS, only waist circumfer-
ence was found to be significantly reduced after supple-
mentation in this study. This trend of change in the waist
circumference was similar to the decline in the incidence
rate of MetS, despite that lowering of waist circumfer-
ence to less than 90/80 cm were not the main contribu-
tors for subjects that showed a release from having MetS
after three months of BG supplementation. Abdominal
obesity is well recognized as a potential etiologic factor of
MetS [38]; hence, reverted central obesity is of signifi-
cance for overall MetS management. This finding from
our study is particularly important for Asians, a popula-
tion that is likely to have metabolic obesity [39].
In general, lyophilized WBG powder capsule prepara-
tions in our study were well tolerated. There were few
adverse events and these were generally mild. In
previous human trials, the most commonly reported
side effects are abdominal pain and diarrhea [24]. Our
study showed that adverse effects were mostly moderate,
including one and two subjects with abdominal pain and
bloat respectively. To our knowledge, this is the first
human trial to evaluate the effects of WBG on MetS.
Limitation
Our study, however, has certain limitations. The rela-
tively small sample size and substantial heterogeneity of
the studied subjects limited our power to detect differ-
ences in many metabolic endpoints. This was an uncon-
trolled trial, so we cannot exclude the placebo effect.
Nevertheless, after discontinuing the supplementation
agent, our subjects were followed up for MetS over an
additional three-month period. On the other hand, a
recent study demonstrated that taking dietary supple-
ments may create an illusory sense of invulnerability
that disinhibits unhealthy behaviors because such sup-
plements are perceived as conferring health advantages
[40]. This might also be a concern as we did not moni-
tor diets and other life-style factors of our subjects
throughout the study period. Generalizability (external
validity) of the trial findings were not defined due to the
WBG capsules used were prepared from a specific vari-
ety of WBG provided by Hualien District Agricultural
Research and Extension Station, Council of Agricultural,
Executive Yuan, Taiwan.
Conclusions
Results of this preliminary study demonstrate the benefi-
cial effects of WBG on MetS in human. Daily dose of
4.8 g lyophilized WBG powder significantly decreased
the MetS incidence rate after three months of supple-
mentation and this improved status remained for one
month, but not additional months, after the supplemen-
tation ceased. This indicates that the washout period
should be at least one month if a crossover study is to
be conducted. Waist circumference also decreased sig-
nificantly after WBG supplementation. No major
adverse effects were observed. Results of this study pro-
vide the justification for double-blinded placebo con-
trolled trials in the future.
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